Avenacy launches the Palonosetron Hydrochloride Injection, USP, in the United States as a therapeutic generic equivalent for Aloxi as approved by the US FDA. The injection is indicated as an antiemetic and is available in 0.25 mg/5 mL (0.05 mg per mL) single-dose vials. To assist with patient safety, the injection features highly differentiated packaging and labeling to support accurate medication selection.